These include increased risk of hypoglycaemia (potentially life-threatening) for sulfonylureas and insulin [95, 96], gastrointestinal side effects for GLP1-RAs [89, 97], urogenital sepsis for SGLT2is [90, 97], and heart failure and altered bone metabolism for thiazolidinediones [98]. This evidence concerns the gene GLP1R and heart failure.